Research across Cancer
Related studies from across the Cancer family.
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Pembrolizumab plus chemotherapy improves ORR and OS in HER2-negative advanced gastric or gastroesophageal junction cancer
Pembrolizumab Plus Chemotherapy Improves Outcomes for Advanced Gastric Cancer
This systematic review and meta-analysis of 3406 patients found that pembrolizumab combined with chemotherapy significantly improved objecti…
Adding the drug pembrolizumab to chemotherapy shows promise in improving survival and response rates for patients with advanced gastric canc…
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers
New Strategies Target Immune Therapies for Pancreatic Cancer
This mini review examines the role of immune checkpoint blockade, vaccines, and cellular therapies in recurrent pancreatic ductal adenocarci…
New research highlights specific ways to better select patients for immune checkpoint inhibitors and advanced cell therapies in pancreatic c…
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Zolbetuximab combined with chemotherapy improves progression-free survival and overall survival in CLDN18.2-expressing gastric cancers
New drug shows promise for advanced stomach and esophageal cancer
This systematic review evaluates zolbetuximab in combination with chemotherapy for patients with advanced G/GEJ adenocarcinoma expressing hi…
A new treatment called zolbetuximab may improve survival rates for patients with specific types of advanced stomach and esophageal cancers.
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…